Search results
Showing 811 to 825 of 1561 results for do not do recommendations
Recommendation ID NG156/1 Question What are the most effective and cost-effective frequencies for monitoring people with unruptured...
What is the best technique for delivering surfactant in a minimally invasive manner?
Recommendation ID NG124/2 Question What is the best technique for delivering surfactant in a minimally invasive manner? Any explanatory
Recommendation ID NG88/3 Question Long-term outcomes of pharmacological and uterine-sparing surgical treatments for HMB associated with
Recommendation ID NG188/1 Question What are the most clinically effective interventions (including social prescribing and structured...
Recommendation ID IPG651/1 Question Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis
Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.
Show all sections
Recommendation ID NG64/5 Question Effectiveness of digital technologies:- How effective and cost effective are digital technologies, such
Recommendation ID NG28/02 Question Non-metformin-based drug treatment combinations to control blood glucose levels: In adults with type
Recommendation ID NG64/2 Question Identifying current practice and provision:- What drug misuse prevention activities are currently used
Recommendation ID CG159/1 Question Adults' uptake of and engagement with interventions for social anxiety disorder:- What methods are...
Recommendation ID NG71/1 Question Combination treatment for Parkinson's disease dementia:- What is the effectiveness of combination...
What are the barriers that women experience to achieving blood glucose targets?
Recommendation ID NG3/3 Question What are the barriers that women experience to achieving blood glucose targets? Any explanatory notes(if
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.
Sorafenib for treating advanced hepatocellular carcinoma (TA474)
Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.